Quarterly report pursuant to Section 13 or 15(d)

Share-Based Compensation Plans

v3.7.0.1
Share-Based Compensation Plans
3 Months Ended
Apr. 29, 2017
Share-Based Compensation Plans  
Share-Based Compensation Plans

11.  Share-Based Compensation Plans

 

For a discussion of our share-based compensation plans, refer to Note 13 in our Annual Report on Form 10-K for the fiscal year ended January 28, 2017.

 

During the first quarter of fiscal 2017, we adopted ASU No. 2016-09, Compensation-Stock Compensation. ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.  The recognition of excess tax benefits and deficiencies related to the vesting of stock-based awards in the statement of earnings and presentation of excess tax benefits on the statement of cash flows were adopted prospectively, with no adjustments made to prior periods.  See Note 8 for additional information.  In addition, upon adoption, we did not change our policy on accounting for forfeitures, which is to estimate the number of awards expected to be forfeited and adjusting the estimate as needed.  Overall, the adoption of ASU 2016-09 did not have a material impact on our financial statements. 

 

The amount of share-based compensation cost is measured based on the grant-date fair value of the instrument issued and is recognized over the vesting period.  Share-based compensation expense recognized for the three months ended April 29, 2017 and April 30, 2016  was $4.7 million and $4.1 million, respectively.  

 

 

Non-Vested Deferred Stock Units, Performance Units and Restricted Stock

 

The following table summarizes the activity of time-based and performance-based (collectively, “DSUs”) awards for the three months ended April 29, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-Average

 

 

 

Units

 

Grant-Date Fair Value

 

 

 

Time-

 

Performance-

 

Time-

 

Performance-

 

 

    

Based

    

Based

    

Based

    

Based

 

Non-Vested at January 28, 2017

 

1,061,965

 

523,948

 

$

24.31

 

$

28.28

 

Granted

 

 —

 

 —

 

 

 —

 

 

 —

 

Vested(1)

 

(350,291)

 

 —

 

 

29.40

 

 

 —

 

Forfeited

 

(11,596)

 

(737)

 

 

23.76

 

 

54.26

 

Non-Vested at April 29, 2017

 

700,078

 

523,211

 

$

21.77

 

$

28.24

 


(1)

Includes 121,993 shares relinquished for tax payments related to vested DSUs for the three months ended April 29, 2017.

 

The following table summarizes the activity of restricted stock for the three months ended April 29, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-
Average

 

 

    

Shares

    

Grant-Date
Fair Value

 

Non-Vested at January 28, 2017

 

36,878

 

$

15.56

 

Granted

 

 —

 

 

 —

 

Vested

 

(36,878)

 

 

15.56

 

Forfeited

 

 —

 

 

 —

 

Non-Vested at April 29, 2017

 

 —

 

$

 —

 

 

Restricted stock awards receive non-forfeitable dividends, if any, when and if paid to shareholders of record at the payment date.

 

As of April 29, 2017, we have unrecognized compensation expense related to non-vested DSUs of approximately $18.5 million, which is expected to be recognized over a weighted-average period of 1.5 years.

 

Stock Options

 

The following table summarizes the activity of stock options for the three months ended April 29, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

Number of

 

Average

 

 

    

Shares

    

Exercise Price

 

Outstanding at January 28, 2017

 

1,194,690

 

$

29.70

 

Granted

 

 —

 

 

 —

 

Exercised

 

 —

 

 

 —

 

Forfeited

 

(1,553)

 

 

52.27

 

Expired

 

(40,243)

 

 

41.23

 

Outstanding at April 29, 2017

 

1,152,894

 

$

29.27

 

Exercisable at April 29, 2017

 

716,137

 

$

33.34

 

 

As of April 29, 2017, we have unrecognized compensation expense related to non-vested stock options of approximately $2.7 million, which is expected to be recognized over a weighted-average period of 1.3 years.